论文部分内容阅读
目的探讨拉贝洛尔联合硫酸镁治疗重度妊娠期高血压的临床疗效。方法选择2014年2月至2016年2月94例重度妊娠期高血压患者的临床记录资料,将其随机分为两组。治疗组47例,应用拉贝洛尔联合硫酸镁治疗;对照组47例,应用硫酸镁治疗。治疗后比较两组疗效。结果治疗组、对照组的总有效率分别为93.62%、78.72%,差异有统计学意义(P<0.05);治疗后,治疗组的舒张压(DBP)、收缩压(SBP)均低于对照组,治疗后的24 h尿蛋白低于对照组,胎儿出生后1 min和5 min的Apgar评分均高于对照组,治疗组产妇发生产后出血、急产、子宫收缩过度、宫颈裂伤的例数均少于对照组,新生儿发生胎儿窘迫、新生儿窒息的例数少于对照组,差异均有统计学意义(P<0.05)。结论拉贝洛尔联合硫酸镁治疗重度妊娠期高血压的临床疗效显著,值得临床推广应用。
Objective To investigate the clinical efficacy of labetalol combined with magnesium sulfate in the treatment of severe gestational hypertension. Methods From February 2014 to February 2016, 94 cases of hypertensive patients with severe gestational hypertension were selected and randomly divided into two groups. Treatment group 47 cases, the application of labetalol combined with magnesium sulfate; control group, 47 cases, the application of magnesium sulfate treatment. After treatment, the two groups were compared. Results The total effective rates of the treatment group and the control group were 93.62% and 78.72%, respectively, with statistical significance (P <0.05). After treatment, the DBP and SBP of the treatment group were lower than those of the control group Group, 24 h urinary protein after treatment was lower than the control group, 1 and 5 min after birth fetal Apgar score were higher than the control group, the treatment group maternal postpartum hemorrhage, emergency delivery, uterine contraction, cervical laceration cases The number of neonatal asphyxia was less than that of the control group. There were significant differences in neonatal asphyxia (P <0.05). Conclusion The clinical efficacy of labetalol combined with magnesium sulfate in the treatment of severe gestational hypertension is significant and worthy of clinical application.